Zacks Research Has Positive Outlook for HALO Q1 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities research analysts at Zacks Research increased their Q1 2026 earnings estimates for Halozyme Therapeutics in a research note issued on Friday, December 26th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings per share of $1.19 for the quarter, up from their previous estimate of $1.17. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q3 2026 earnings at $1.70 EPS, FY2026 earnings at $6.22 EPS, Q1 2027 earnings at $1.55 EPS and Q2 2027 earnings at $1.78 EPS.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The company had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The firm’s revenue was up 22.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.27 EPS.

HALO has been the subject of several other reports. Leerink Partners upgraded Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 target price for the company in a report on Tuesday, October 14th. Benchmark boosted their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Weiss Ratings restated a “hold (c+)” rating on shares of Halozyme Therapeutics in a report on Monday, December 22nd. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $56.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Finally, Morgan Stanley dropped their price target on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research report on Monday, October 20th. Six equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Hold” and a consensus target price of $75.10.

Halozyme Therapeutics Stock Up 0.7%

Shares of NASDAQ:HALO opened at $68.87 on Monday. The stock has a market capitalization of $8.10 billion, a P/E ratio of 14.50, a price-to-earnings-growth ratio of 0.37 and a beta of 0.95. The stock’s 50-day moving average price is $67.34 and its 200-day moving average price is $65.57. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. Halozyme Therapeutics has a 12-month low of $47.50 and a 12-month high of $79.50.

Insider Buying and Selling at Halozyme Therapeutics

In other news, COO Cortney Caudill sold 4,263 shares of Halozyme Therapeutics stock in a transaction dated Saturday, November 1st. The shares were sold at an average price of $65.19, for a total transaction of $277,904.97. Following the sale, the chief operating officer owned 12,737 shares of the company’s stock, valued at approximately $830,325.03. The trade was a 25.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $68.48, for a total transaction of $136,960.00. Following the completion of the transaction, the director directly owned 42,952 shares of the company’s stock, valued at approximately $2,941,352.96. The trade was a 4.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 85,661 shares of company stock valued at $6,036,837. 2.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Lindenwold Advisors INC raised its stake in shares of Halozyme Therapeutics by 2.5% in the third quarter. Lindenwold Advisors INC now owns 8,221 shares of the biopharmaceutical company’s stock worth $603,000 after purchasing an additional 201 shares during the last quarter. Allworth Financial LP increased its holdings in Halozyme Therapeutics by 322.5% in the 3rd quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock worth $2,914,000 after buying an additional 30,331 shares in the last quarter. IFP Advisors Inc raised its position in Halozyme Therapeutics by 17.8% in the 3rd quarter. IFP Advisors Inc now owns 5,206 shares of the biopharmaceutical company’s stock worth $382,000 after buying an additional 785 shares during the last quarter. Swiss Life Asset Management Ltd purchased a new position in Halozyme Therapeutics in the 3rd quarter worth about $426,000. Finally, CIBC Private Wealth Group LLC lifted its stake in Halozyme Therapeutics by 12.8% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,891 shares of the biopharmaceutical company’s stock valued at $212,000 after acquiring an additional 329 shares during the period. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.